Bridgebio analyst coverage
WebApr 14, 2024 · BridgeBio Pharma, Inc. ( NASDAQ:BBIO – Get Rating )’s share price gapped up before the market opened on Thursday after SVB Securities raised their price target on the stock from $25.00 to $27.00.... WebApr 6, 2024 · Analyst Price Forecast Suggests 76.38% Upside As of April 6, 2024, the average one-year price target for BridgeBio Pharma is $26.78. The forecasts range from a low of $18.18 to a high of...
Bridgebio analyst coverage
Did you know?
WebApr 10, 2024 · NASDAQ:BBIO BridgeBio Pharma - BBIO News Today $13.55 -0.26 (-1.88%) (As of 03/17/2024 12:00 AM ET) Compare Today's Range $13.26 $13.93 50-Day Range $7.45 $18.55 52-Week Range $4.98 $19.94 Volume 7.12 million shs Average Volume 2.88 million shs Market Capitalization $2.05 billion P/E Ratio N/A Dividend Yield … WebOct 12, 2024 · BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in …
WebApr 6, 2024 · Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy. The company focus on genetic diseases because they …
WebIn August 2024, LianBio entered into a strategic alliance with BridgeBio, a commercial-stage biopharmaceutical company focused on genetic diseases and cancers with clear genetic drivers, to develop and commercialize BridgeBio’s programs in China and other major Asian markets. WebFeb 15, 2024 · BridgeBio has some very significant price catalysts arriving in 2024 promising substantial upside should they be positive. Most important is Phase 3 interim data from Part B of a pivotal study of...
WebApr 9, 2024 · On Friday, March 3rd, Neil Kumar sold 120,000 shares of BridgeBio Pharma stock. The shares were sold at an average price of $10.96, for a total value of …
WebJul 26, 2024 · BridgeBio Pharma (BridgeBio) is a commercial-stage biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. BridgeBio’s pipeline of development programs ranges from early science to advanced … ironside swim schoolWebMar 17, 2024 · BridgeBio Pharma, Inc. ( NASDAQ:BBIO) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's forecasts. The analysts have sharply increased... ironside sports physioWebMar 23, 2024 · BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of … ironside st north port fl 34288WebBridgeBio Pharma, Inc. (BBIO) NasdaqGS - NasdaqGS Real Time Price. Currency in USD. Follow. 2W 10W 9M. 13.58 +0.74 (+5.76%) At close: 04:00PM EDT. 13.80 +0.22 … ironside state school tuckshopWebMar 7, 2024 · Get The Latest BBIO Stock Forecast, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat. Should You Buy or Sell BridgeBio Pharma Stock? Get The Latest BBIO Stock Forecast, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat. Skip to main content S&P 500 3,992.01(+0.14%) DOW … ironsidearms.netWebMar 7, 2024 · BridgeBio Pharma, Inc. (BridgeBio) is a commercial-stage biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. BridgeBio's pipeline of development programs ranges from early science to … ironside trail dr groveland flWebBridgeBio Media Contact: Grace Rauh T: (917) 232-5478 E: [email protected] BridgeBio Investor Contact: Katherine Yau T: (516) 554-5989 E: … port wine buyers